Tag: nasdaq:azrx

September 29, 2019

5 Top NASDAQ Biotech and Pharma Stocks: Big Rise for Ovid Therapeutics

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...
September 25, 2019

AzurRx BioPharma Dips on Phase 2 Trial Results for MS1819

Shares of the company tumbled more than 20 percent on Wednesday following the release of Phase 2 trial results for...
September 25, 2019

AzurRx BioPharma Announces Positive Phase 2 Trial Results of MS1819

The company's treatment, MS1819, was being evaluated in patients to treat exocrine pancreatic insufficiency in cystic fibrosis.
May 23, 2019

AzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial

AzurRX BioPharma (NASDAQ:AZRX) has announced it has reached its enrollment target of 30 to 35 patients for its ongoing Phase...
June 29, 2018

AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency

AzurRx BioPharma (NASDAQ:AZRX) a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced, in partnership with Mayoly...